Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease

详细信息    查看全文

• 作者：Hideki Fujii ; ^{fhideki@med.kobe-u.ac.jp} ; Yuriko Yonekura ; Kentaro Nakai ; Keiji Kono ; Shunsuke Goto ; Shinichi Nishi
• 关键词：VS-105 ; Vitamin D analog ; CKD-MBD ; FGF23 ; Klotho
• 刊名：The Journal of Steroid Biochemistry and Molecular Biology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：167
• 期：Complete
• 页码：55-60
• 全文大小：816 K
• 卷排序：167

文摘

VS-105 is a novel VDRA which has lesser effects on serum calcium levels. Serum P levels were higher in the paricalcitol-treated groups than in the VS-105-treated groups. The urinary excretion of P was lower in the paricalcitol-treated groups than in the VS-105-treated groups. VS-105 affects serum FGF23 levels less than did paricalcitol. VS-105 ameliorates the VDR and Klotho expression in the kidney more than paricalcitol.